	Application No.	Applicant(s)
Notice of Allowability	10/045,545	MAINES, MAHIN D.
	Examiner	Art Unit
	Sheridan L. Swope	1652
The MAILING DATE of this communication apper All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this apport or other appropriate communication GHTS. This application is subject to	plication. If not included will be mailed in due course. THIS
1. This communication is responsive to <u>February 22, 2005</u> .		
2. The allowed claim(s) is/are <u>1 and 9-12</u> .		
3. The drawings filed on 14 January 2002 are accepted by the Examiner.		
 4. ☐ Acknowledgment is made of a claim for foreign priority uner a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 3. ☐ Copies of the certified copies of the priority documents 	been received. been received in Application No	
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the	84(c)) should be written on the drawing header according to 37 CFR 1.121(c	ngs in the front (not the back) of d).
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)		atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Dat	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date		
4. Examiner's Comment Regarding Requirement for Deposit	8. X Examiner's Stateme	nt of Reasons for Allowance
of Biological Material	9. Other	

DETAILED ACTION

Applicant's response and Declaration under 1.132, received February 22, 2005, to the Action on the Merits of this case, mailed August 17, 2004, are acknowledged. It is acknowledged that Claim 1 has been amended. Claims 1 and 8-12 are pending and are hereby reconsidered.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Cancel Claim 8.

For Claim 9, replace –claim 8– with –claim 1–.

Authorization for this examiner's amendment was given in a telephone interview with Ted Merkel on April 8, 2005.

Allowable Subject Matter

Claims 1 and 9-12 are allowed.

The following is an examiner's statement of reasons for allowance:

All elected Claims, 1 and 9-12, are limited to a method of modifying cell structure by introducing into a mammalian cell a polynucleotide encoding the biliverdin reductase of SEQ ID NO: 2 or variants thereof. The utility of said method, as being a means to modify cell structure, is credible based on introduction of a polynucleotide encoding human biliverdin reductase into HeLa cells, resulting in enhanced cell size, actin microspike formation, and polar cell

Application/Control Number: 10/045,545 Page 3

Art Unit: 1652

morphology (Figs 1-6 and the 1.132 Declaration of February 22, 2005). Biliverdin reductase is an enzyme involved in the breakdown of heme and, specifically, converts biliverdin to bilirubin. The prior art does not teach a role for biliberdin reductase, or the bilirubin product, in enhanced

cell size, actin microspike formation, or polar cell morphology.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheridan L. Swope whose telephone number is 571-272-0943. The examiner can normally be reached on M-F; 9:30-7 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published application may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on the access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sheridan Lee Swope, Ph.D.

PRIMARY EXAMINER
GROUP 1800

Keluca link